Expert Perspectives on Integrating Immuno-Oncology Therapeutics Into the Management of Metastatic Triple-Negative Breast Cancer
  • CME
  • CE

Review the latest developments in immuno-oncology strategies for managing metastatic TNBC with this set of expert commentaries, including optimal use of immune checkpoint inhibition, management of immune-related toxicities, and future directions.
Sarah Donahue, MPH, NP
David B. Page, MD
Hope S. Rugo, MD
Peter Schmid, MD, PhD, FRCP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 14, 2020 Expiration: May 13, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with metastatic triple-negative breast cancer who are most likely to benefit from immune checkpoint inhibitors as single agents or in combination with chemotherapy
  • Plan first-line treatment with immune checkpoint inhibitors as single agents or in combination with chemotherapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune checkpoint inhibitors for patients with progressive triple-negative breast cancer after one or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune checkpoint inhibitors in patients with breast cancer
  • Recommend ongoing clinical trials assessing single-agent and/or combination immunotherapy approaches for appropriate patients with breast cancer

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Genentech

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Sarah Donahue, MPH, NP

Oncology Nurse Practitioner
Hellen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, has no relevant conflicts of interest to report.
David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

David B. Page, MD, has disclosed that he has received consulting fees from Brooklyn ImmunoTherapeutics and Genentech; funds for research support from Bristol-Myers Squibb, Brooklyn ImmunoTherapeutics, and Merck; and fees for non-CME/CE services from Genentech and Novartis.
Hope S. Rugo, MD

Professor of Medicine
Director, Breast Cancer and Clinical Trials Education
Division of Hematology/Oncology
Department of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support from Daiichi, Eisai, Genentech, Immunomedics, Lilly, MacroGenics, Merck, Novartis, OBI, Odonate, Pfizer, and Seattle Genetics; has received consulting fees from Ionis and Celltrion; and has received support for travel from Amgen, AstraZeneca, Daiichi, MacroGenics, Merck, Pfizer, and Puma.
Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Bart's Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Bart's Hospital
London, United Kingdom

Peter Schmid, MD, PhD, FRCP, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, and Roche and funds for research support paid to his institution from Genentech, Novartis, OncoGenex, and Roche and that his spouse has received consulting fees from Genentech and Roche.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with metastatic triple-negative breast cancer.

Goal

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with metastatic triple-negative breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-058-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 14, 2020, through May 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: July 2, 2020

A short slideset from Clinical Care Options covering key clinical insights for the current management of HR+/HER2- advanced breast cancer.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Mary Jo Fidler, MD discusses key data in lung malignancies from ASCO 2020 and optimization of therapeutic benefit through management of cancer cachexia syndrome

person default Mary Jo Fidler, MD Released: June 30, 2020

Slides from Neelima Denduluri, MD, FASCO: HER2-targeted TKIs and antibody-drug conjugates for HER2-positive metastatic breast cancer, from CCO

Neelima Denduluri, MD, FASCO Released: June 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?